Fresh off ASCO myeloma data, Legend Bio gets $424M in biotech's biggest IPO of 2020

Legend Biotech, a Nanjing, China-based developer of cell therapies for cancer, is raising just over $420 million in an initial public offering, announcing Friday the pricing of 18.4 million shares at $23 apiece.